Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

E. Roekevisch (Lead / Corresponding author), M. M. G. Leeflang, M. E. Schram, L. E. Campbell, W. H. Irwin McLean, S. Kezic, J. D. Bos, P. I. Spuls, M. A. Middelkamp-Hup

Research output: Contribution to journalLetter

3 Citations (Scopus)
146 Downloads (Pure)

Abstract

Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)1745-1746
Number of pages2
JournalBritish Journal of Dermatology
Volume177
Issue number6
Early online date19 Nov 2016
DOIs
Publication statusPublished - 8 Jan 2018

Keywords

  • Atopic dermatitis
  • Atopic eczema
  • Filaggrin
  • Skin barrier
  • Mutation
  • Azathioprine
  • Methotrexate
  • Immunosuppressive treatment
  • Treatment outcome

Fingerprint Dive into the research topics of 'Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment'. Together they form a unique fingerprint.

  • Cite this